The common marmoset, CaUlithrix jacchus, can be infected with human varicella-zoster virus (VZV), both wild-type strain KMcC and attenuated vaccine strain Oka/Merck. Infection was accomplished with either whole-cell-associated or cell extract VZV by combined oral-nasal-conjunctival application and was characterized by substantial and persistent anti-VZV antibody responses. The infectivity of VZV for marmosets was destroyed by treatment of inocula with heat or UV light. Diluted inocula with as few as 40 PFU/ml were infectious for marmosets. The lungs were demonstrated to be a major site of viral replication; both the presence of viral antigens and signs of pneumonia were demonstrated in lung tissues. Four serial passages of VZV KMcC were carried out in C. jacchus by a process of in vitro isolation and culturing of VZV from infected lung tissue and reapplication of the cultured isolates to fresh animals. The isolated viruses were identified as VZV both serologically and by restriction endonuclease analyses. The C. jacchus infectivity model should prove useful for determining the efficacy of subunit and live recombinant VZV vaccines as well as for the study of zoster.
To date, there has been no reliable, widely accepted animal model of infection by human varicella-zoster virus (VZV). Infection of old-world monkeys with a simian varicella virus that is antigenically distinct from human VZV was described (5) , but this model has limited reliability in testing VZV subunit antigens (K. F. Soike, P. M. Keller, and R. W. Ellis, J. Med. Virol., in press). Other studies (1, 2) with VZV in pygmy marmosets and rhesus monkeys provided evidence only suggestive of infection. Guinea pigs also have been studied as an infectivity model for VZV (8, 9) . The most recent study (13) reported the development of significant anti-VZV antibody titers in weanling guinea pigs which were inoculated intratracheally or intrabronchially. The lungs of the animals showed pneumonialike changes at 7 days postinoculation, but attempts to isolate VZV from the animals were uniformly negative. Before the appearance of that report (13) , we found that the application of VZV by a combined oral-nasal-conjunctival (0-N-C) route to common marmosets, Callithrix jacchus, induced substantial and persisting anti-VZV antibody responses. We now describe definitive evidence of VZV infection of these animals.
MATERIALS AND METHODS
Marmosets. Young adult (1 to 3 years) C. jacchus marmosets bred in captivity were obtained from Charles River Breeding Laboratories, Inc. Adult Saguinus labiatus marmosets (5 to 8 years) were caught in the wild. During experimentation, all animals were housed and used in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Inoculations and bleedings were done during anesthetic treatment with ketamine hydrochloride. Combined O-N-C inoculation was done by application of 1.0 ml of VZV into the mouth, 1.0 ml into the nostrils, and 0.1 ml onto the conjunctivae of the animals. Parenteral inoculation consisted of administering * Corresponding author.
1.0 ml intravenously plus 1.0 ml intramuscularly. Animals were bled weekly, and citrated plasmas were collected.
VZV inocula. Strain KMcC (10) had a history of four passages in WI-38 cells plus four passages in MRC-5 cells. The Oka/Merck vaccine strain of VZV (12) also was grown in MRC-5 cells. Cell-associated VZV inocula consisted of trypsinized infected cell preparations in culture medium with 2% fetal bovine serum and contained about 5 x 106 PFU/ml. Cell extract VZV inocula were sonically disrupted, mechanically harvested preparations in sucrose-phosphate-glutamate solution (3) supplemented with 1.0% human serum albumin and had lower titers (see below). Inocula for serial passages of VZV KMcC in C. jacchus were cell-associated preparations.
Titrations of viral infectivity. MRC-5 cell monolayers at 50 to 75% confluence were inoculated, incubated for 1 week at 35°C, and stained with Coomassie brilliant blue to detect plaques.
Physical treatments of viral inocula. To address the issue of VZV KMcC replication in C. jacchus, we inoculated animals with heat-inactivated or unheated VZV (Table 2) . A typical anti-VZV response was induced by cell-associated, unheated VZV given by the combined O-N-C route; in contrast, no response was induced in animals given the heated inoculum. Furthermore, an unheated cell extract VZV inoculum also induced a substantial anti-VZV response when given by the combined O-N-C route of inoculation, while no response was induced in animals given the heated inoculum. Cell extract inocula administered parenterally elicited anti-VZV antibodies whether they were heat inactivated or not (data not shown). This result established that the antigenicity of the heated inocula was not destroyed by heating and further indicated that the failure of heat-inactivated inocula to induce anti-VZV responses when given by the combined O-N-C route was due to the absence of live virus, i.e., replication, and not to a loss of antigenicity. These observations were reinforced by another study in which an alternate means of VZV inactivation was used. UV treatment of both cell-associated and cell extract preparations of VZV negated the ability of these preparations to induce anti-VZV antibodies when given by combined O-N-C inoculation ( Table 3) . The lowlevel response of one of the animals to the irradiated inoculum may have been caused by a low level of residual live VZV (21 PFU/ml) in the inoculum.
The induction of anti-VZV antibody responses by highly diluted inocula applied by the combined O-N-C route provided additional evidence for viral replication (Table 4 ). An animal given an inoculum of cell-associated VZV diluted to contain only 40 PFU/ml elicited an anti-VZV response comparable in magnitude to that produced by inocula with a much higher level of PFU. Consistent with the need for replication, there was a delay in the time to the onset of detectable anti-VZV antibodies (6 weeks). Furthermore, inocula of 400 and 40,000 PFU/ml also were effective in eliciting anti-VZV antibody responses when given by the combined O-N-C route. These responses also were characterized by an apparent delay in the time to the onset of anti-VZV antibodies, as compared with the results in the animal that received 4,000,000 PFU/ml.
The replication of VZV in C. jacchus does not appear to depend on the strain of VZV used. Both the Oka/Merck vaccine strain and KMcC appeared to be equally effective in inducing anti-VZV responses when given by the combined O-N-C route (Table 5) . The serial transmission of VZV in vivo represents the most straightforward proof that VZV does infect C. jacchus (Table 6 ). VZV was isolated successfully in vitro from lungs of inoculated animals at each of four serial in vivo viral passages. The isolations were accomplished readily by cocultivating lung tissue at 6 or 7 days postinoculation of the animals with MRC-5 cells. Each isolate produced a cytopathic effect in MRC-5 cells within 1 week of primary inoculation, and each isolate was passaged successfully in MRC-5 cells. Inocula for serial in vivo transmission were prepared at the final in vitro passage. Since some nonhuman primates are known to harbor a simian varicella virus capable of inducing VZV-like cytopathic effects in vitro, it was important to show that all in vitro isolates were human VZV. This was established for each isolate by three independent criteria (Table 6 ). The patterns of DNA fragments generated by digestion with BglI, HpaI, and PstI restriction endonucleases showed that all three isolates and nonmarmoset-passaged VZV KMcC had patterns essentially identical to each other and to those of EF, another clinical isolate (7) . The only differences noted were in the isolates from the second and third marmoset passages. These had a single band shift in each of the three digestion patterns. These differences may have been due to technical variations or may indeed reflect the adaptation and selection of variants as a result of replication in the animals or in cell cultures. The overwhelming similarities of all three isolates to the original strain, KMcC, and to EF demonstrated that the isolates were clearly human VZV. It also should be noted that every isolate induced typical anti-VZV antibody responses in C. jacchus when given by the combined O-N-C route and that no evidence of anti-VZV antibodies was ever seen in any of the 62 uninoculated C. jacchus marmosets.
Pathological evidence of successful infection of C. jacchus with VZV also was obtained. VZV antigens were detectable by indirect immunofluorescence on impression slides of lung tissue at day 6 postinoculation but not on lung tissue preparations at day 0 or 13 postinfection. At day 6, VZV antigens were detected in alveolar interstitial spaces and in enlarged alveolar macrophages as well as speckled in the background cell debris. Sections of lungs (hematoxylin-eosin stained) from these same animals showed evidence of viral pneumonia, most pronounced at day 6 but still evident at day 13; sections at days 0 and 20 were normal. These findings are consistent with VZV infection of the lungs of these animals.
Our findings in C. jacchus provide the best evidence to date forthe development of a meaningful animal model for infection by human VZV. The lungs appear to be a major site of viral replication, but it has not been established whether viral infection spreads beyond this site. No visible lesions of mucous membranes or skin have been noted in any of the animals to date, nor has substantial evidence of a latent infection yet been obtained. Preliminary attempts to date to isolate VZV from blood, lymph nodes, liver, spleen, and various nerve tissues have been unsuccessful but continue to be pursued. We continue to serially transmit VZV in C. jacchus. With continued refinement, it is hoped that this animal model may be useful in studies of the prevention of primary infections with VZV and of the prevention of zoster. It also may be useful in discriminating-between wild-type and liye, attenuated vaccine strains of VZV. Finally, it may allow evaluation of the efficacy of experimental vaccines, based either upon incorporation of foreign genes encoding desired vaccine antigens into live VZV (6b) or upon subunit glycoprotein antigens (4, 6, 6a) .
We have recently obtained evidence that C. jacchus marmosets can also be infected with VZV administered by the intravenous route. Doses of 1:250-to 1:500-diluted harvests of cell-associated VZV containing 4,600 to 6,000 PFU induced anti-VZV antibodies in five of six C. jacchus marmosets. The magnitude of the antibody responses was similar to that reported for the animals infected by the O-N-C route. That the VZV antigen content of these inocula was inadequate to induce measurable anti-VZV antibodies, short of viral replication, was shown with four control animals. These received the same inocula after heat inactivation, and none showed anti-VZV antibody responses.
